retatrutide clinical trial dose retatrutide Triple hormone receptor agonist for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a Retatrutide Dosing: Weekly Injections, Clinical

PubMed evidence trail Research sources used to frame this page For Retatrutide and Thyroid: Side Effects, Risks and How to Manage (2026), FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available

US health policy and prescription drug coverage of FDA-approved medications for the treatment of obesity

The Bottom Line Retatrutide is one of the most promising metabolic innovations in decades

The combination of GLP-1, GIP and glucagon receptor activation provided superior glycemic control compared to existing GLP-1-based therapies

Side effects from a recent step up are still settling

Those with heart conditions should discuss this with their physician before starting treatment